24 January 2017  
EMEA/H/C/003953 
Public statement 
Budesonide/Formoterol Teva Pharma B.V. 
Withdrawal of the marketing authorisation in the European Union 
On 16 December 2016, the European Commission withdrew the marketing authorisation for 
Budesonide/Formoterol Teva Pharma B.V. (budesonide / formoterol) in the European Union (EU). The 
withdrawal was at the request of the marketing authorisation holder, Teva Pharma B.V., which notified 
the European Commission of its decision not to market the product in the EU for commercial reasons.  
Budesonide/Formoterol Teva Pharma B.V. was granted marketing authorisation in the EU on 19 
November 2014 for treatment of asthma. The marketing authorisation was initially valid for a 5-year 
period. Budesonide/Formoterol Teva Pharma B.V. was of DuoResp Spiromax, which is marketed in 
several EU countries. 
The European Public Assessment Report (EPAR) for Budesonide/Formoterol Teva Pharma B.V. will be 
updated accordingly to indicate that the marketing authorisation is no longer valid. 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
 
  
 
 
 
 
 
